Abstract
The new guidelines of the European Commission on infant and follow-on formulae stipulate that from February 2020 onwards all such products sold in the European Union must contain a high amount of 20–50 mg/100 kcal of the omega 3-fatty acid docosahexaenoic acid (DHA, ≈0.5–1% of fatty acids), while there is no requirement to include arachidonic acid (ARA, omega 6-fatty acids). This novel compositional concept for infant formulae has raised controversy and concerns because there is no accountable evidence for its suitability and safety. In accordance with the European Academy of Paediatrics, the Committee on Nutrition of the German Society for Pediatrics and Adolescent Medicine recommends the use of infant and follow-on formulae that contain at least the same amount of ARA along with DHA, as long as no convincing data on the suitability and safety of alternative concepts are available based on adequately designed and powered clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
